scholarly journals Selective Interactions of O-Methylated Flavonoid Natural Products with Human Monoamine Oxidase-A and -B

Molecules ◽  
2020 ◽  
Vol 25 (22) ◽  
pp. 5358
Author(s):  
Narayan D. Chaurasiya ◽  
Jacob Midiwo ◽  
Pankaj Pandey ◽  
Regina N. Bwire ◽  
Robert J. Doerksen ◽  
...  
Keyword(s):  
Natural Products ◽  
Enzyme Inhibition ◽  
Selective Inhibition ◽  
Monoamine Oxidase A ◽  
Inhibition Kinetics ◽  
Free Energies ◽  
Mao B ◽  
Mao A ◽  
Enzyme Inhibition Kinetics ◽  
Binding Free Energies

A set of structurally related O-methylated flavonoid natural products isolated from Senecio roseiflorus (1), Polygonum senegalense (2 and 3), Bhaphia macrocalyx (4), Gardenia ternifolia (5), and Psiadia punctulata (6) plant species were characterized for their interaction with human monoamine oxidases (MAO-A and -B) in vitro. Compounds 1, 2, and 5 showed selective inhibition of MAO-A, while 4 and 6 showed selective inhibition of MAO-B. Compound 3 showed ~2-fold selectivity towards inhibition of MAO-A. Binding of compounds 1–3 and 5 with MAO-A, and compounds 3 and 6 with MAO-B was reversible and not time-independent. The analysis of enzyme-inhibition kinetics suggested a reversible-competitive mechanism for inhibition of MAO-A by 1 and 3, while a partially-reversible mixed-type inhibition by 5. Similarly, enzyme inhibition-kinetics analysis with compounds 3, 4, and 6, suggested a competitive reversible inhibition of MAO-B. The molecular docking study suggested that 1 selectively interacts with the active-site of human MAO-A near N5 of FAD. The calculated binding free energies of the O-methylated flavonoids (1 and 4–6) and chalcones (2 and 3) to MAO-A matched closely with the trend in the experimental IC50′s. Analysis of the binding free-energies suggested better interaction of 4 and 6 with MAO-B than with MAO-A. The natural O-methylated flavonoid (1) with highly potent inhibition (IC50 33 nM; Ki 37.9 nM) and >292 fold selectivity against human MAO-A (vs. MAO-B) provides a new drug lead for the treatment of neurological disorders.

scholarly journals Evaluation of the Isoflavone Genistein as Reversible Human Monoamine Oxidase-A and -B Inhibitor

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Najla O. Zarmouh ◽  
Samia S. Messeha ◽  
Faisel M. Elshami ◽  
Karam F. A. Soliman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Therapeutic Agent ◽  
Docking Studies ◽  
Monoamine Oxidase A ◽  
Inhibition Kinetics ◽  
Mao B ◽  
Therapeutic Drugs ◽  
Mao A ◽  
Luminescence Assay

Monoamine oxidases inhibitors (MAOIs) are effective therapeutic drugs for managing Parkinson’s disease (PD) and depression. However, their irreversibility may lead to rare but serious side effects. As finding safer and reversible MAOIs is our target, we characterized therecombinant human(h) MAO-A and MAO-B inhibition potentials of two common natural isoflavones, genistein (GST) and daidzein (DZ) using luminescence assay. The results obtained showed that DZ exhibits partial to no inhibition of the isozymes examined while GST inhibitedhMAO-B (IC50of 6.81 μM), and itshMAO-A inhibition was more potent than the standard deprenyl. Furthermore, the reversibility, mode of inhibition kinetics, and tyramine oxidation of GST were examined. GST was a time-independent reversible and competitivehMAO-A andhMAO-B inhibitor with a lowerKiofhMAO-B (1.45 μM) thanhMAO-A (4.31 μM). GST also inhibitedhMAO-B tyramine oxidation and hydrogen peroxide production more thanhMAO-A. Docking studies conducted indicated that the GST reversibility andhMAO-B selectivity of inhibition may relate to C5-OH effects on its orientation and its interactions with the threonine 201 residue of the active site. It was concluded from this study that the natural product GST has competitive and reversible MAOs inhibitions and may be recommended for further investigations as a useful therapeutic agent for Parkinson’s disease.

Longan seed polyphenols inhibit α-amylase activity and reduce postprandial glycemic response in mice

2021 ◽  
Author(s):  
Ting He ◽  
lei zhao ◽  
Yan Chen ◽  
Xin Zhang ◽  
Zhuoyan Hu ◽  
...  
Keyword(s):  
Enzyme Inhibition ◽  
Amylase Activity ◽  
Glycemic Response ◽  
Inhibition Assay ◽  
Inhibition Kinetics ◽  
Enzyme Inhibition Kinetics ◽  
Longan Seed ◽  
Kinetics Of

The effects of longan seed polyphenols (LSPs) on postprandial glycemic response in mice were investigated, enzyme inhibition kinetics of LSPs against α-amylase were studied using an inhibition assay in vitro,...

Are Coumarin Derivatives The New Keys in Depression Treatment? In silico Key-lock Fitting Analysis of Coumarin Derivatives with Monoamine Oxidase-A

2020 ◽  
Vol 7 ◽  
Author(s):  
Dilara Karaman ◽  
Kemal YELEKCI ◽  
Serkan ALTUNTAS
Keyword(s):  
Monoamine Oxidase ◽  
Protein Interactions ◽  
In Silico ◽  
Monoamine Oxidase A ◽  
Coumarin Derivatives ◽  
Discovery Studio ◽  
Mao B ◽  
Drug Candidates ◽  
Mao A ◽  
Molecular Modeling Studies

The research of ligand-protein interactions with in silico molecular modeling studies on the atomic level gives an opportunity to be understood the pharmacokinetic metabolism of anti-depressant drug candidates. Monoamine oxidase (MAO) enzymes are important targets for the treatment of depressive disorder. MAOs have two isoforms as MAO-A and MAO-B being responsible for catalyzing of neurological amines. In this study a new series of coumarin derivatives were designed for selective and reversible inhibition of MAO-A enzyme. 3rd, 5th and 7th positions were selected to be placed of five different side groups. Docking procedures of each ligand in M series of these novel 125 compounds were executed with 10 runs by using AutoDock4.2 software. Docking results were analyzed via Discovery Studio 3.1 (Biovia Inc.). The most promising compounds were M118 and M123 according to selectivity index, SI (MAO-B/MAO-A)=180 fold and 209 fold and Ki values 7.25 nM and 12.01 nM, respectively. Overall, the current study provided significant knowledge for the development of new anti-depressant drugs.

Understanding the bioaccessibility, α-amylase and α-glucosidase enzyme inhibition kinetics of Allmania nodiflora (L.) R.Br. ex Wight polyphenols during in vitro simulated digestion

2022 ◽  
Vol 372 ◽  
pp. 131294
Author(s):  
Gayathri Jagadeesan ◽  
Kasipandi Muniyandi ◽  
Ashwini Lydia Manoharan ◽  
Gayathri Nataraj ◽  
Parimelazhagan Thangaraj
Keyword(s):  
Enzyme Inhibition ◽  
Inhibition Kinetics ◽  
Simulated Digestion ◽  
Enzyme Inhibition Kinetics ◽  
Kinetics Of

Evaluation of enzyme inhibition kinetics in drug–drug interactions

2014 ◽  
Vol 222 ◽  
pp. 133-134 ◽  
Author(s):  
Ang Chen ◽  
Xuan Qin ◽  
Yu Tang ◽  
Mingyao Liu ◽  
Xin Wang
Keyword(s):  
Drug Interactions ◽  
Enzyme Inhibition ◽  
Inhibition Kinetics ◽  
Enzyme Inhibition Kinetics

scholarly journals Isolation and Biological Evaluation of Prenylated Flavonoids from Maclura pomifera

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Yerkebulan Orazbekov ◽  
Mohamed A. Ibrahim ◽  
Serjan Mombekov ◽  
Radhakrishnan Srivedavyasasri ◽  
Ubaidilla Datkhayev ◽  
...  
Keyword(s):  
Monoamine Oxidase ◽  
Opioid Receptors ◽  
Cannabinoid Receptors ◽  
Biological Evaluation ◽  
Monoamine Oxidase A ◽  
Moderate Activity ◽  
Significant Activity ◽  
Mao B ◽  
Maclura Pomifera ◽  
Mao A

Phytochemical analysis of the ethanolic extract of Maclura pomifera fruits yielded four new compounds (I–IV) along with eleven known compounds (V–XV). The crude extract exhibited significant activity towards cannabinoid receptors (CB1: 103.4% displacement; CB2: 68.8% displacement) and possibly allosteric interaction with δ and μ opioid receptors (−49.7 and −53.8% displacement, resp.). Compound I was found to be possibly allosteric for κ and μ opioid receptors (−88.4 and −27.2% displacement, resp.) and showed moderate activity (60.5% displacement) towards CB1 receptor. Compound II exhibited moderate activity towards cannabinoid receptors CB1 and CB2 (47.9 and 42.3% displacement, resp.). The known compounds (V–VIII) exhibited prominent activity towards cannabinoid receptors: pomiferin (V) (IC50 of 2.110 and 1.318 μM for CB1 and CB2, resp.), auriculasin (VI) (IC50 of 8.923 μM for CB1), warangalone (VII) (IC50 of 1.670 and 4.438 μM for CB1 and CB2, resp.), and osajin (VIII) (IC50 of 3.859 and 7.646 μM for CB1 and CB2, resp.). The isolated compounds were also tested for inhibition of human monoamine oxidase-A and monoamine oxidase-B enzymes activities, where all the tested compounds showed fewer inhibitory effects on MAO-A compared to MAO-B activities: auriculasin (VI) (IC50 of 1.91 and 45.98 μM for MAO-B and MAO-A, resp.).

Sign in / Sign up

Export Citation Format

Share Document